130 related articles for article (PubMed ID: 19386079)
1. Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: implications for protocol biopsy policy.
Roberts IS; Stratopoulos C; Zilvetti M; Reddy S; Friend PJ
Transpl Int; 2009 Aug; 22(8):831-6. PubMed ID: 19386079
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
3. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
[TBL] [Abstract][Full Text] [Related]
4. Modifying cyclosporine associated renal allograft dysfunction.
Mohapatra N; Vanikar AV; Patel RD; Trivedi HL
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):770-4. PubMed ID: 19736471
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
6. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
8. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
9. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis in renal transplant recipients on various immunosuppressive regimens.
Atasever A; Bacakoglu F; Toz H; Basoglu OK; Duman S; Basak K; Guzelant A; Sayiner A
Nephrol Dial Transplant; 2005 Apr; 20(4):797-802. PubMed ID: 15703207
[TBL] [Abstract][Full Text] [Related]
11. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
[TBL] [Abstract][Full Text] [Related]
12. Does mycophenolate mofetil increase the incidence of infections in renal transplant recipients?
Prokopenko E; Scherbakova E; Vatazin A; Pasov S; Budnikova N; Agafonova S
Drugs Exp Clin Res; 2005; 31(5-6):199-205. PubMed ID: 16425976
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
14. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients.
Michielsen LA; van Zuilen AD; Verhaar MC; Wisse BW; Kamburova EG; Joosten I; Allebes WA; van der Meer A; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Hilbrands LB
Nephrol Dial Transplant; 2019 Aug; 34(8):1417-1422. PubMed ID: 30561730
[TBL] [Abstract][Full Text] [Related]
15. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
[TBL] [Abstract][Full Text] [Related]
18. The utility of 6-month protocol renal biopsy under modern immunosuppression.
Yango A; Gohh R; Wang LJ; Morrissey P; Shih M; Lowery K; Charpentier K; Gautam A; Mendonca C; Kumar S; Dworkin L; Monaco A
Clin Nephrol; 2008 Dec; 70(6):490-5. PubMed ID: 19049705
[TBL] [Abstract][Full Text] [Related]
19. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
